Theralase, Inc.
Theralase Technologies Inc. is a pioneering clinical-stage biopharmaceutical company dedicated to developing light-activated therapies targeting cancer, bacteria, and viruses. With a focus on innovative treatments such as Anti-Cancer Therapy (ACT) employing patented Photo Dynamic Compounds (PDCs), the company aims to safely and effectively destroy various cancers and infectious agents. Theralase combines expertise in physics, engineering, medicine, biology, chemistry, immunology, pharmaceutical drug design, and clinical research to advance its healthcare solutions. The company is actively involved in clinical trials, including Phase II studies for Non-Muscle Invasive Bladder Cancer (NMIBC), and is expanding its pipeline to include treatments for Glioblastoma Multiforme (GBM), Non-Small Cell Lung Cancer (NSCLC), and COVID-19, among others. Theralase's mission is to 'Destroy Cancer at the Speed of Light®' and 'Heal Pain at the Speed of Light®', striving to revolutionize cancer and infectious disease treatment through light-activated therapies.
Industries
Nr. of Employees
small (1-50)
Patents
Sonodynamic therapy using sonodynamically activated coordination complexes of transition metals as sensitizing agents
US-11813330-B2
View DetailsMethod for treating conditions associated with hyperproliferating cells comprising combined administration of a cannabinoid receptor agonist and radiation therapy
US-11793818-B2
View DetailsVaccine containing cancer cells inactivated by photodynamic treatment with metal-based coordination complexes, and immunotherapy method using same
US-11464798-B2
View DetailsPhotodynamic compounds and methods for activating them using ionizing radiation and/or other electromagnetic radiation for therapy and/or diagnostics
US-10335608-B2
View Details
Sonodynamic therapy using sonodynamically activated coordination complexes of transition metals as sensitizing agents
US-11813330-B2
View DetailsMethod for treating conditions associated with hyperproliferating cells comprising combined administration of a cannabinoid receptor agonist and radiation therapy
US-11793818-B2
View DetailsVaccine containing cancer cells inactivated by photodynamic treatment with metal-based coordination complexes, and immunotherapy method using same
US-11464798-B2
View DetailsPhotodynamic compounds and methods for activating them using ionizing radiation and/or other electromagnetic radiation for therapy and/or diagnostics
US-10335608-B2
View DetailsProducts
Clinical-stage intravesical photodynamic drug candidate for NMIBC
A photodynamic drug candidate formulated for intravesical administration and local activation by laser light for treatment of non-muscle invasive bladder cancer; advanced through early human studies into a pivotal Phase II clinical study.
Tumor-targeted formulation strategies for enhanced uptake
Formulation approaches combining photoactive compounds with carrier proteins or targeting moieties to increase tumor localization and enable treatment of deep or difficult-to-reach tumors and combination regimens.
Clinical laser systems for activation and therapeutic use
Multi-wavelength pulsed laser systems engineered for clinical activation of photoactive compounds and for therapeutic, non-pharmaceutical applications; devices have undergone safety testing and national certification processes.
Photodynamic viral inactivation platform for vaccine material
A preclinical platform to inactivate virus-grown material via treatment with photoactive compounds followed by activation to produce inactivated viral preparations for vaccine research and immunogenicity testing.
Clinical-stage intravesical photodynamic drug candidate for NMIBC
A photodynamic drug candidate formulated for intravesical administration and local activation by laser light for treatment of non-muscle invasive bladder cancer; advanced through early human studies into a pivotal Phase II clinical study.
Tumor-targeted formulation strategies for enhanced uptake
Formulation approaches combining photoactive compounds with carrier proteins or targeting moieties to increase tumor localization and enable treatment of deep or difficult-to-reach tumors and combination regimens.
Clinical laser systems for activation and therapeutic use
Multi-wavelength pulsed laser systems engineered for clinical activation of photoactive compounds and for therapeutic, non-pharmaceutical applications; devices have undergone safety testing and national certification processes.
Photodynamic viral inactivation platform for vaccine material
A preclinical platform to inactivate virus-grown material via treatment with photoactive compounds followed by activation to produce inactivated viral preparations for vaccine research and immunogenicity testing.
Services
Sponsored and collaborative research agreements with academic and government laboratories to support preclinical evaluation, optimization and translational studies of photoactive compounds and formulations.
Design and conduct of Phase I/Ib and pivotal Phase II clinical studies with integrated safety monitoring, pharmacokinetics and efficacy endpoints, plus preparation of regulatory submissions and support for site activation.
Manufacture of clinical-grade photoactive compound batches under Good Manufacturing Practice for use in human studies and support for IND/CTA-enabling activities.
Sponsored and collaborative research agreements with academic and government laboratories to support preclinical evaluation, optimization and translational studies of photoactive compounds and formulations.
Design and conduct of Phase I/Ib and pivotal Phase II clinical studies with integrated safety monitoring, pharmacokinetics and efficacy endpoints, plus preparation of regulatory submissions and support for site activation.
Manufacture of clinical-grade photoactive compound batches under Good Manufacturing Practice for use in human studies and support for IND/CTA-enabling activities.
Expertise Areas
- Photodynamic therapy research and development
- Early-phase oncology clinical trial management (Phase I/II)
- Drug-device combination engineering
- Preclinical oncology models and in vivo efficacy testing
Key Technologies
- Photodynamic therapy (photoactive small molecules)
- Optical (near-infrared) laser activation
- Radiation-activated drug activation
- Small-molecule-triggered drug activation
News & Updates
Theralase® plans to extend the expiry date of 4,800,000 share purchase warrants from June 30, 2025, to June 30, 2028, with warrants issued in 2023, exercisable at $0.35 per share.
Theralase® closed a $571,000 private placement, issuing 2,855,000 units at $0.20 each, supporting its Phase II bladder cancer trial, Rutherrin® development, and corporate needs.
Theralase® successfully completed its 2025 Annual General Meeting, sharing strategic plans for 2025–2026 focused on clinical advancements and commercialization.
Theralase® will present preclinical data on Rutherrin® at ASTRO 2025, highlighting tumor targeting, immune activation, and survival benefits.
Theralase® plans to extend the expiry date of 4,800,000 share purchase warrants from June 30, 2025, to June 30, 2028, with warrants issued in 2023, exercisable at $0.35 per share.
Theralase® closed a $571,000 private placement, issuing 2,855,000 units at $0.20 each, supporting its Phase II bladder cancer trial, Rutherrin® development, and corporate needs.
Theralase® plans to extend the expiry date of 4,800,000 share purchase warrants from June 30, 2025, to June 30, 2028, with warrants issued in 2023, exercisable at $0.35 per share.
Theralase® closed a $571,000 private placement, issuing 2,855,000 units at $0.20 each, supporting its Phase II bladder cancer trial, Rutherrin® development, and corporate needs.
Theralase® successfully completed its 2025 Annual General Meeting, sharing strategic plans for 2025–2026 focused on clinical advancements and commercialization.
Theralase® will present preclinical data on Rutherrin® at ASTRO 2025, highlighting tumor targeting, immune activation, and survival benefits.
Theralase® plans to extend the expiry date of 4,800,000 share purchase warrants from June 30, 2025, to June 30, 2028, with warrants issued in 2023, exercisable at $0.35 per share.
Theralase® closed a $571,000 private placement, issuing 2,855,000 units at $0.20 each, supporting its Phase II bladder cancer trial, Rutherrin® development, and corporate needs.